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Abstract b1-Integrins are essential for angiogenesis. The
mechanisms regulating integrin function in endothelial
cells (EC) and their contribution to angiogenesis remain
elusive. Brag2 is a guanine nucleotide exchange factor for
the small Arf-GTPases Arf5 and Arf6. The role of Brag2 in
EC and angiogenesis and the underlying molecular mech-
anisms remain unclear. siRNA-mediated Brag2-silencing
reduced EC angiogenic sprouting and migration. Brag2-
siRNA transfection differentially affected a5b1- and
aVb3-integrin function: specifically, Brag2-silencing
increased focal/fibrillar adhesions and adhesion on b1-
integrin ligands (fibronectin and collagen), while reducing
the adhesion on the aVb3-integrin ligand, vitronectin.
Consistent with these results, Brag2-silencing enhanced
surface expression of a5b1-integrin, while reducing
surface expression of aVb3-integrin. Mechanistically,
Brag2-mediated aVb3-integrin-recycling and b1-integrin
endocytosis and specifically of the active/matrix-bound
a5b1-integrin present in fibrillar/focal adhesions (FA),
suggesting that Brag2 contributes to the disassembly of FA
via b1-integrin endocytosis. Arf5 and Arf6 are promoting
downstream of Brag2 angiogenic sprouting, b1-integrin
endocytosis and the regulation of FA. In vivo silencing of
the Brag2-orthologues in zebrafish embryos using mor-
pholinos perturbed vascular development. Furthermore,
in vivo intravitreal injection of plasmids containing Brag2-
shRNA reduced pathological ischemia-induced retinal and
choroidal neovascularization. These data reveal that Brag2
is essential for developmental and pathological angiogen-
esis by promoting EC sprouting through regulation of
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adhesion by mediating b1-integrin internalization and link
for the first time the process of b1-integrin endocytosis
with angiogenesis.
Keywords Angiogenesis  Brag2  Endocytosis 
Integrins  Migration
Introduction
Angiogenesis, the formation of new capillaries from pre-
existing ones by endothelial cell (EC) sprouting, is
involved in many physiologic and pathologic conditions,
including embryonic development, wound healing, rheu-
matoid arthritis, tumor growth and metastasis and prolif-
erative retinopathy [5]. Beyond endothelial cells also
proangiogenic cells circulating in blood contribute to
angiogenesis by paracrine effects [28, 32].
Integrins are heterodimeric transmembrane proteins
consisting of non-covalent bound a- and b-subunits
mediating cell adhesion to extracellular matrix (ECM)
proteins and bidirectional signaling [24]. Beyond angio-
genic growth factors, there is evidence that integrins are
implicated in angiogenesis [23]. Specifically, endothelial-
restricted deficiency of b1-integrins and of the a5-integrin
subunit of the b1-integrins impairs in vivo angiogenesis [4,
31, 49, 50, 52]. However, the effects of increased integrin-
dependent EC adhesion on angiogenesis are still elusive.
Integrins are regulated by distinct mechanisms: (a) the
level of expression, (b) regulation of integrin affinity and
integrin valency (avidity) and (c) integrin trafficking,
which affects integrin localization in the cells and the
assembly/disassembly of focal adhesions. Previous studies
from our group provided insight in the regulation of inte-
grin affinity in EC and their role in angiogenesis [6].
However, less is known about the mechanisms of integrin
trafficking in EC and specifically their contribution to
angiogenesis. Cell migration requires a tight spatiotemporal
regulation of focal adhesion assembly and disassembly.
Integrin trafficking (endocytosis/recycling) seems to be
essential for cell migration by contributing to the turnover of
focal and fibrillar adhesions during migration [8–10, 17, 53].
Arf6 is a small GTPase cycling between an inactive
GDP- and active GTP-bound form involved in the regu-
lation of actin cytoskeleton and receptor trafficking [14, 19,
35]. Several stimuli, such as integrin binding to fibronectin,
as well as stimulation with growth factors, cytokines and
guidance molecules may induce the activation of Arf6 in
EC [18, 20, 27, 44]. Arf6 can be activated by several
guanine exchange nucleotide factors (GEFs) [7]. Brag2
(GEP100/IQSEC1) is a GEF activating the small Arf-
GTPases Arf4, Arf5 and Arf6 [33, 48] and is expressed in
EC [20, 45]. Brag2 was found to promote the invasive
activity of breast cancer cells [34] and myoblast fusion [11,
37]. Furthermore, Brag2 was shown to be involved in
trafficking processes such as the endocytosis of synaptic
AMPA-receptors, E-Cadherin recycling, and phagocytosis
of monocytes [21, 46, 47]. Silencing of Brag2 in HeLa cells
increased the surface expression of b1-integrins [15] and a
later study indicated that Brag2 might contribute to b1-
integrin endocytosis in HeLa cells [33]. However, the role
of Brag2 in the regulation of integrins in EC was not
studied thus far. In EC VEGF stimulation induces the
association of VEGFR2 with Brag2 and induces the acti-
vation of Arf6 [20]. Interestingly, Semaphorin 3E-induced
over-activation of the Brag2/Arf6 pathway results in col-
lapse of EC and angiogenesis inhibition [45]. On the other
side, it was demonstrated that silencing of Brag2 reduces
endothelial tube formation in vitro and angiogenesis in a
model of Angioreactor-induced angiogenesis [20]. Never-
theless, the role of Brag2 for in vivo physiological devel-
opmental and pathological angiogenesis and the underlying
molecular mechanisms remain elusive.
In our present work, we provide direct evidence that Brag2
plays a key role in the regulation of integrin-dependent
angiogenic functions such as sprouting, migration and adhe-
sion of EC in vitro. Specifically, we show that Brag2 differ-
entially affects b1- and aVb3-integrin function and promotes
angiogenic sprouting by contributing to the endocytosis of b1-
integrins, thereby Arf5- and Arf6-dependently regulating
focal/fibrillar adhesions and reducing adhesion in EC. In
accordance with these results, silencing of Brag2 impaired
developmental angiogenesis and vascular patterning in zeb-
rafish. Moreover, in vivo knockdown of Brag2 significantly
reduced pathological angiogenesis in mice. Taking together,
our work for the first time links a mechanism of integrin
endocytosis with the process of angiogenesis.
Materials and methods
Cells
Human umbilical vein endothelial cells (HUVEC) were
purchased from Lonza (Basel, Switzerland) and cultured in
endothelial basal medium (EBM) supplemented with 1 lg/
mL hydrocortisone, 12 lg/mL bovine brain extract, 50 lg/
mL gentamicin, 50 ng/mL amphotericin-B, 10 ng/mL
epidermal growth factor, and 10 % fetal calf serum until
the third passage. Cos-7 cells were cultured in DMEM
containing 10 % fetal calf serum.
RNAi transfections
To silence Brag2, a5-integrin, Arf5, Arf6 we performed
transfection of small-interfering RNA (siRNA) duplex
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using Lipofectamine RNAiMAX (Invitrogen) according to
the manufacturer’s protocol. Brag2 siRNAs were synthe-
sized by Eurogentec and Sigma-Aldrich. The Brag2 target
sequences were 50-AGAACUCGGUGACGUACAG-30
(Brag2 siRNA-1), and 50-GGAUGCAGUUCUCCUUU-
GA-30 (Brag2 siRNA-2). A nonrelated scrambled siRNA
was used as a control. The target sequence targeting a5-
integrin is 50-AATCCTTAATGGCTCAGACAT-30 (Qia-
gen). For silencing human Arf5 and Arf6, we used ON-
TARGETplus SMARTPool siRNAs and the respective
controls from Dharmacon.
Plasmid constructs and transfection
COS-7 cells (1.5 9 105 cells per 3.5 cm-well) were grown
to 60–70 % confluence and then transfected with 4 lg
plasmids using Superfect transfection reagent (QIAGEN)
according to the manufacturer’s protocol. The Brag2a-GFP
(GEP100-GFP) plasmid was kindly provided by Dr. J.E.
Casanova (Department of Cell Biology, University of
Virginia Health System, Charlottesville, VA, USA). The
Brag2a-DSec-GFP, Brag2a-DPH-GFP plasmids were
kindly provided by Dr. M. Vaughan (Pulmonary-Critical
Care Medicine Branch, National Heart, Lung, and Blood
Institute, National Institutes of Health, Bethesda, USA) and
by Dr. A. Someya (Juntendo University, School of Medi-
cine, Tokyo). The Arf5-GFP and Arf6-GFP were pur-
chased by Addgene. Site-directed mutagenesis was
performed to generate the rapid cycling Arf5-T161A-GFP
and Arf6-T1571A-GFP mutants with the QuikChange II
XL site-directed mutagenesis kit (Stratagene/Agilent,
Waldbronn, Germany).
Spheroid-based angiogenic sprouting assay
Endothelial-cell spheroids were generated as described
previously [6]. In brief, HUVEC were suspended in culture
medium containing 0.2 % (w/v) carboxymethylcellulose
(Sigma-Aldrich) 24 h after siRNA transfection and seeded
in round-bottomed 96-well plates (Greiner) to form
spheroids. The following day, spheroids were embedded
into rat collagen I (BD Biosciences) containing gels.
Angiogenic sprouting was stimulated where indicated by
adding human vascular endothelial growth factor (VEGF,
50 ng/mL; PeproTech, Hamburg, Germany) containing
medium after gel polymerization. In the experiments with
the neutralizing integrin antibodies endothelial-cell spher-
oid embedded in the collagen gels were incubated with
control antibody (BD Biosciences), anti-aVb3-integrin
antibody (Clone LM609) or anti-b1-integrin antibody
(clone: mAb13, BD Biosciences) in the presence of VEGF.
After 24 h, images were acquired using an Axiocam MR
digital camera with an Axiovert 100 M inverted
microscope using as objective a Plan-NEOFLUAR (at
109/0.30) and were processed using AxioVision Rel 4.5
digital imaging software (all from Carl Zeiss, Jena, Ger-
many). In vitro capillary sprouting was quantified by
measuring the cumulative sprout length of each spheroid
using a computer-assisted microscope [AxioVision 4.5
software (Carl Zeiss)] and the mean cumulative sprout
length of 10 spheroids/condition was calculated.
Cell–matrix adhesion
Ninety-six-well plates were coated overnight with 1 lg/mL
soluble recombinant human collagen I (Millipore) or
2.5 lg/mL human fibronectin (Sigma), 2.5 lg/mL human
vitronectin (Millipore), or 2.5 lg/mL bovine serum albu-
min (BSA) in PBS at 4 C and then blocked for 1 h at room
temperature with 3 % (w/v) heat-inactivated (2 h, 56 C)
bovine serum albumin (BSA; Sigma-Aldrich). HUVEC
were stained (48 h after the siRNA transfection) with 2070-
bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acet-
oxymethyl ester (BCECF, AM; Molecular Probes) and
after detachment with trypsin were resuspended in EBM
containing 0.05 % BSA. Then, 50,000 cells/well were
seeded and allowed to attach for 60 min at 37 C. After
removal of non-adhering cells by washing with warm
EBM, adherent cells were quantified in triplicates with a
fluorescence plate reader (Synergy HT; Bio-Tek Instru-
ments, Bad Friedrichshall, Germany). Data are presented as
mean specific adhesion % of input ± SEM.
Zebrafish lines, morpholinos and vessel quantification
Embryos of AB wt and the tg(fli1:EGFP) line were raised
and staged as described [30]. Embryos were kept in E3
solution at 28.5 C with or without 0.003 % 1-phenyl-2-
thiourea (Sigma) to suppress pigmentation and staged
according to somite number or hours post-fertilization [16].
Morpholinos were diluted in 0.1 M KCl and 1 nL of
morpholino dilution was injected through the chorion of
one-cell or two-cell stage embryos. To attenuate possible
off-target effects, a p53 Mo was co-injected 1.5-fold to the
other morpholinos used. The following splice-blocking
morpholinos (Gene Tools) were used:
IQSEC1a-MO-A: CTCCACCTGTGAAAACAAGGAT
GAA (targeting intron 4/exon 5 boundary); 2.5 ng per
embryo
IQSEC1a-MO-B: GCTGACTGAATGGAGAAACAA
TAAC (targeting intron 7/exon 8 boundary); 2 ng per
embryo
IQSEC1b-MO-A: CTGGCTAAACAAAGAAACACAC
CAC (targeting intron4/exon 5 boundary); 2 ng per
embryo
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IQSEC1b-MO-B: AACCCCTTTCAAAACGCAAGCA-
CAA (targeting intron5/exon6 boundary); 3 ng per
embryo
control morpholino (control Mo): CCTCTTACCTCAG
TTACAATTTATA
Quantification of vessel defects in tg(fli1:EGFP)
embryos of intersomitic vessels (ISV) and the dorsal lon-
gitudinal anastomotic vessel (DLAV) was performed as
recently described [16]. Parachordal vessel/parachordal
lymphangioblasts (PL) were quantified as recently descri-
bed [16]. In brief, embryos were divided in three groups
according to the presence (2), partial (1) or complete
absence (0) of the parachordal lymphangioblasts. For the
quantification of CCV defects following criteria were used:
2—broad, all cells have intercellular contacts to each other
and are homogenously regular distributed, not branched;
1—thin vessel, branched, not all cells have contacts to each
other and as consequence there exist gaps between cells;
0—very thin or interrupted vessel, shortened vessel with
brittle structure.
In the experiments of the Supplemental Figure S6 fol-
lowing conditions were compared in order to exclude off-
target effects of double injections of morpholinos: (1)
Control MO ? p53 MO; (2) IQSEC1a-MO-B ? p53 MO;
(3) IQSEC1a-MO-B ? Control MO; (4) IQSEC1b-MO-
A ? Control MO and (5) IQSEC1b-MO-B ? Control MO.
Retinopathy of prematurity (ROP) model and model
of laser-induced choroidal neovascularization
All animal experiments were approved by the Animal Care
and Use Committee at the NEI/National Institutes of
Health (NIH) and were performed according to the NIH
guidelines and regulations. Briefly, 7-day-old (p7) C57BL/
6J mice were exposed to 75 % oxygen in a chamber for
5 days with their nursing mothers. At p12, the mice were
returned to room air. Brag2 shRNA vector
(TRCN0000340707, Open Biosystems) or the control
vector PLKO.1 (Sigma) was delivered to the eyes of
anesthetized neonatal mice by intravitreal injections with
the in vivo-jetPEITM reagent (Polyplus Transfection) at
p12. The eyes with severe vitreous hemorrhage or dis-
turbed development after injection were excluded from
assessment. Mice were euthanized and the eyes harvested
at P17. Whole-mount retinae were stained with Isolectin
GS-IB4 Alexa Fluor 488 (Invitrogen). Image analysis was
performed using a Carl Zeiss Imager Z1 and the image-
processing software: AxioVision (Carl Zeiss), Photoshop
CS (Adobe). Quantification of neovascularization was
performed as previously described [13].
In the model of laser-induced choroidal neovasculari-
zation female mice (age 6 weeks) were used for
experiments. Four laser spots were introduced (75 lm spot
size, 75 ms, 90 mW power; OcuLight Infrared Laser Sys-
tem 810 nm, Iridex) in the area surrounding the optic disk
in the eye. Mouse Brag2 shRNA (2 lg/eye, Open Biosys-
tems, catalogue number TRCN0000340707) or PLKO1
empty plasmid was injected intravitreally 2 days before
laser treatment together with the transfection reagent
in vivo-jetPEITM (Polyplus Transfection, New York, NY)
according to the manufacturer’s instructions. The CNV
area was analyzed at 1 week after laser treatment using
isolectin B4 (IB4, Invitrogen) staining. For eye tissue
(choroid and retina) isolation, the anterior segment and the
vitreous of the eyes were removed. The retina was dis-
sected from the RPE-choroid eye cup. The dissected tissues
were fixed for morphological analysis.
Statistical analysis
Continuous variables are expressed as mean ± SEM or
where indicated mean ± SD. Comparisons between groups
were analyzed by t test (2-sided) or analysis of variance
(ANOVA) (post hoc test: Newman–Keuls) for experiments
with more than 2 subgroups (GraphPad Prism version 5.0). In
the zebrafish experiments the Kruskal–Wallis test was used.
P values\0.05 were considered statistically significant.
Results
Role of Brag2 in the VEGF-induced activation of Arf6
Consistent with previous studies [20, 45] HUVEC and
human microvascular endothelial cells express Brag2a and
Brag2b protein as assessed by Western blot (data not
shown). Moreover, we confirmed that VEGF stimulation
rapidly increases the activity of the small GTPase Arf6 in
EC (supplemental Figures S1A and S1B) as previously
reported [18, 20, 27]. To address the role of Brag2 as
guanine nucleotide exchange factor (GEF) in the VEGF-
induced activation of Arf6, we employed siRNA targeting
Brag2. Silencing of Brag2 with siRNAs effectively reduced
the expression of Brag2 mRNA and protein (supplemental
Figures S1C and S1D) while not significantly affecting the
expression of other Arf6 GEFs such as Cytohesin-1, Cy-
tohesin-2 and Cytohesin-3 (data not shown). Furthermore,
silencing of Brag2 reduced basal and VEGF-induced acti-
vation of Arf6 (supplemental Figures S1A and S1B). Thus,
Brag2 is required for Arf6 activation under basal condi-
tions and upon VEGF stimulation. Likewise, Semaphorin
3E also activates Arf6 in a Brag2-dependent manner;
however, the Semaphorin 3E-induced Arf6-activation is
delayed and much more sustained ([44] and data not
shown).
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Role of Brag2 for angiogenic sprouting, tube formation
and EC migration
We next explored the contribution of endogenous Brag2 in
angiogenesis in vitro. Silencing of Brag2 with siRNA
significantly reduced the capability of 3-dimensional EC
spheroids of angiogenic sprouting in the presence or
absence of VEGF (Fig. 1a, b) or bFGF (data not shown) in
comparison to scrambled siRNA-transfected HUVEC. As a
control for the specificity of this approach, a second Brag2-
siRNA was generated and gave similar results (Fig. 1a, and
supplemental Figures S1C and S1D). Moreover, transient
overexpression of Brag2a-GFP rescued the inhibition of
angiogenic sprouting exerted by a siRNA targeting the
30UTR region of Brag2 (data not shown). In accordance
with these data, silencing of Brag2 significantly impaired
tube/network-forming activity of HUVEC in the matrigel
assay (Fig. 1c, d). Furthermore, Brag2 silencing signifi-
cantly impaired the VEGF-induced 3-dimensional invasion
and the 2-dimensional migration of HUVEC on fibronectin
in a scratch wound assay (Fig. 2a, b), while not signifi-
cantly affecting HUVEC proliferation (Supplemental Fig-
ure S1E). Taken together, Brag2 is essential for in vitro
angiogenesis and EC migration.
Brag2 differentially regulates b1- and aVb3-integrins
The regulation of integrin-mediated cell adhesion on
matrix proteins is essential for cell migration [42]. There-
fore, we studied the role of Brag2 in the b1-integrin-
tube formation in matrigel
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Fig. 1 Silencing of Brag2 with
siRNA blocks in vitro
angiogenesis. a HUVEC were
transfected with siRNAs
targeted against Brag2 or
scrambled siRNA. Two
different sequences were used
as indicated by Brag2siRNA1
and Brag2siRNA2. Three-
dimensional in vitro angiogenic
sprouting in a spheroidal culture
system with collagen-embedded
spheroids in the presence or
absence (control) of VEGF
50 ng/mL. The mean
cumulative length of sprouts per
spheroid was assessed after 24 h
(#P \ 0.05 vs. scrambled
siRNA, *P \ 0.05 vs.
scrambled ? VEGF, n = 4).
b Representative figures of
spheroidal sprouting assay
performed with HUVEC
transfected as indicated with
Brag2-siRNA or scrambled
siRNA in the presence of VEGF
50 ng/mL. c HUVECs were
seeded on Matrigel Basement
Membrane Matrix 48 h after
transfection with scrambled
siRNA, Brag2siRNA1 or
Brag2siRNA2. The length of
capillary-like structures/
networks was measured in 5
different high-power fields by
light microscopy after 24 h
(*P \ 0.05 vs. scrambled
siRNA, n = 3–6).
d representative micrographs of
the tube-forming activity of
HUVEC after transfection with
scrambled siRNA or Brag2
siRNA
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dependent EC adhesion on ECM proteins such as fibro-
nectin and collagen. Interestingly, silencing of Brag2 sig-
nificantly enhanced the steady-state b1-integrin-dependent
HUVEC adhesion on fibronectin and collagen and
significantly increased spreading (cell area) on fibronectin
in comparison to scrambled siRNA-transfected HUVEC
(Fig. 2c–e). Remarkably, the effect on adhesion seems to
be specific for the b1-integrins since silencing of Brag2
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Fig. 2 Role of Brag2 for EC migration and b1-integrin-dependent
adhesion and spreading. a 3-Dimensional migration (invasion) assay
on Matrigel Basement Membrane Matrix with HUVEC transfected
with siRNAs targeted against Brag2 or scrambled siRNA. After 48 h,
cells were seeded in the upper chamber of modified Boyden
chambers. HUVEC migration was assessed using VEGF (50 ng/
mL) as chemoattractant (in the lower chamber). Data are presented as
mean migrated cells/field ± SEM (*P \ 0.05 vs. VEGF ? scram-
bled siRNA, n = 8). b 2-Dimensional migration assay (wound
healing/scratch wound assay) with HUVEC transfected with siRNAs
targeted against Brag2 or scrambled siRNA. Data are presented as
mean migration distance ± SEM (*P \ 0.05 vs. scrambled siRNA,
n = 4). c, d Adhesion assay with EC transfected with siRNAs
targeted against Brag2 or scrambled siRNA on fibronectin (c) or
collagen (d). After 48 h, cells were allowed to adhere for 1 h on
coated wells (n = 5). Data are presented as mean percentage of
adhering cells % input ± SEM (*P \ 0.05 vs. scrambled siRNA).
e Spreading assay of HUVEC on fibronectin 48 h after transfection
with scrambled or Brag2 siRNA. Data are presented as mean cell
area ± SEM (*P \ 0.05 vs. scrambled siRNA, n = 3). f, g Immuno-
fluorescence staining for b1-integrin (f) or active a5-integrin subunit
(clone SNAKA51) (g) in HUVEC adhering on fibronectin, 48 h after
transfection with scrambled siRNA or Brag2 siRNA. Microphoto-
graphs demonstrating focal and fibrillar adhesions were acquired at
the basal surface of the cells, where focal/fibrillar adhesions are
localized. Red fluorescence indicates the active a5-integrin or b1-
integrin subunit, green fluorescence indicates phalloidin staining for
F-actin and white color indicates nuclei. The white arrows indicate
focal and fibrillar adhesions
Page 6 of 19 Basic Res Cardiol (2014) 109:404
123
significantly reduced HUVEC adhesion on the b3-integrin
ligand, vitronectin (supplemental Figure S1F). In accordance
with these results, silencing of Brag2 increased b1-integrin-
and active a5-integrin-containing focal and fibrillar adhe-
sions and enhanced the formation of actin stress fibers in
HUVEC adhering on fibronectin, suggesting that Brag2 is a
negative regulator of b1-integrin-containing focal/fibrillar
adhesions (Fig. 2f, g). Quantification of the focal/fibrillar
adhesion area by performing immunofluorescent staining
with an antibody recognizing activated/matrix-bound a5b1-
integrins localized in fibrillar and partly in focal adhesions
(clone SNAKA51) [12] confirmed these results (Fig. 2g and
Supplemental Figure S1G). These data raised the hypothesis
that Brag2 may contribute to the disassembly of b1-integrin-
containing focal/fibrillar adhesions in EC.
Silencing of Brag2 increases a5b1-integrin-
and reduces aVb3-integrin surface expression on EC
To understand the differential function of Brag2 in EC
adhesion, we determined the role of Brag2 for the cell
surface expression of b1- and aVb3-integrins. Indeed,
silencing of Brag2 by siRNA increased the cell surface
abundance of the a5b1-integrin on HUVEC as assessed by
FACS (Fig. 3a), while not affecting the total a5-integrin
and b1-integrin protein expression as assessed by West-
ernblot (Supplemental Figures S2A and S2B). In addition,
silencing of Brag2 also slightly increased the expression of
a3b1- and a6b1-integrin on the EC surface (data not
shown). In contrast, knockdown of Brag2 significantly
reduced the surface expression of the aVb3-integrin
scrambled
siRNA 
Brag2 
siRNA 
5-integrins phalloidin merge 
scrambled
F
G
siRNA 
Brag2 
siRNA 
1-integrins phalloidin merge Fig. 2 continued
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(Supplemental Figures S2C and S2D), which is in accor-
dance with the reduction of EC adhesion to the aVb3-
integrin ligand, vitronectin (supplemental Figure S1F).
Thus, silencing of Brag2 differentially affects b1- and b3-
integrin expression on the EC surface and adhesion on
fibronectin and vitronectin.
Brag2 promotes angiogenesis by regulating of a5b1-
integrin expression on the EC surface
b1-integrin inhibition with neutralizing antibodies signifi-
cantly blocked angiogenic sprouting of HUVEC, while
aVb3-integrin inhibition did not (Supplemental Figure
S1H). In line with these results, genetic evidence supports
that b1-integrins are essential for in vivo angiogenesis [3,
4, 41, 49, 52]. Since silencing of Brag2 enhanced b1-
integrin-dependent adhesion and a5b1-integrin surface
expression, we investigated the underlying mechanisms
affecting b1-integrin function in EC. Specifically, we
addressed the role of the enhanced surface expression of
a5b1-integrins for the inhibitory effect of Brag2 silencing
on angiogenic sprouting. For this purpose, we performed
silencing of a5-integrin subunit of the a5b1-integrin using
a low dose of siRNA in Brag2 siRNA-transfected HUVEC,
in order to achieve a slight reduction of the a5-integrin on
the cell surface reaching the levels observed in scrambled
siRNA-transfected EC as assessed by FACS (Fig. 3b).
Strikingly, a reduction of the a5b1-integrin surface abun-
dance in the Brag2-siRNA-transfected HUVEC partly
rescued the inhibitory effect of Brag2 silencing on angio-
genic sprouting (Fig. 3b, c). Hence, Brag2 partly mediates
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Fig. 3 Role of Brag2-mediated regulation of b1-integrin surface
expression for angiogenic sprouting. a Steady-state surface expression
of the a5b1-integrin on EC as assessed by FACS, 48 h after
transfection with scrambled siRNA or Brag2 siRNA. Data are
presented as specific mean fluorescence intensity ± SEM (*P \ 0.05
vs. scrambled siRNA, n = 5). b HUVEC were transfected with
scrambled siRNA (siScr), Brag2siRNA (siBrag2) or with the
combination of Brag2siRNA and low dose (6.5 nM) of siRNA
targeting a5-integrin (low-dose siITGA5). After 48 h, the steady-state
surface expression of the a5b1-integrin on EC was assessed by FACS.
Data are presented as specific mean fluorescence intensity % of
siScr ± SEM (*P \ 0.05 vs. siScr, n = 8). c Spheroidal sprouting
assays using HUVEC transfected with scrambled siRNA (siScr),
Brag2 siRNA (siBrag2) or Brag2 siRNA and low-dose ITGA5 siRNA
(siBrag2 ? low-dose siITGA5) were performed. The mean cumula-
tive length of sprouts per spheroid was assessed after 24 h. Data are
presented as mean cumulative length of sprouts per spheroid ± SEM
(*P \ 0.05, siBrag2 vs. siBrag2 ? low-dose siITGA5, n = 7)
cFig. 4 Brag2 mediates b1-integrin internalization. a Immunofluores-
cent staining for Brag2 (green fluorescence) and activated/matrix-
bound a5b1-integrin (clone SNAKA51) present in focal and fibrillar
adhesions. The blue color indicates nuclear staining (DAPI). The
white arrow indicates Brag2 co-localized or in the vicinity of focal/
fibrillar focal adhesions. TIRF microscopy with a 9100 objective was
performed, in order to assess the co-localization in the basal level of
HUVEC. b Pulse-chased endocytosis assay based on immunofluo-
rescence staining for b1-integrin subunit in HUVEC adhering on
fibronectin, 48 h after transfection with scrambled siRNA or Brag2
siRNA. HUVEC were allowed to internalize b1-integrin for 10 min
as described in the ‘‘Materials and methods’’. Red fluorescence
indicates the internalized b1-integrin subunit, green fluorescence
indicates phalloidin staining for F-actin and white color indicates
nuclei. c Pulse-chased endocytosis assay of the b1-integrin subunit in
HUVEC as determined with FACS as described in the ‘‘Materials and
methods’’ section. Data are presented as mean internalized b1-
integrin % of total surface b1-integrin ± SEM (*P \ 0.05 vs.
scrambled siRNA, n = 6). d, e Biochemical biotinylation-based
internalization assay of b1-integrin (d) and of activated a5-integrin
subunit (e) were performed for the indicated time-points (0, 5 and
15 min) as described in the ‘‘Materials and methods’’ section. Data
are presented as mean internalized integrin % of total surface
integrin ± SEM (*P \ 0.05 vs. scrambled siRNA at 15 min of
endocytosis, n = 3)
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angiogenic sprouting by regulating the surface expression
of the a5b1-integrin on the EC surface. Remarkably,
silencing of the a5-integrin subunit employing a high dose
of a5-integrin-siRNA leading to a profound reduction of
the a5-integrin on the EC surface significantly blocked
in vitro angiogenic sprouting (Supplemental Figure S2E)
suggesting that a tight regulation of b1-integrin surface
expression is essential for efficient angiogenic sprouting.
Brag2 promotes endocytosis of b1-integrins
and recycling of aVb3-integrins in EC
As assessed by TIRF microscopy, Brag2 partly co-localized
with focal/fibrillar adhesions containing activated a5b1-
integrins indicating a direct role of Brag2 in the regulation of
focal/fibrillar adhesions (Fig. 4a). Mechanisms of endocy-
tosis were shown to contribute to the disassembly of focal
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adhesions during cell migration [8–10, 17]. Therefore, we
hypothesized that Brag2 may mediate endocytosis/inter-
nalization of b1-integrins in EC. Silencing of Brag2 with
siRNA significantly reduced the internalization of the b1-
integrin as assessed by a pulse-chased immunofluorescence-
based endocytosis assay (Fig. 4b). To quantify the
internalization of b1-integrins, we additionally employed a
FACS-based endocytosis assay (Fig. 4c). Indeed, silencing
of Brag2 with siRNA significantly reduced b1-integrin
internalization (Fig. 4c). Since binding of antibodies to sur-
face receptors and cell detachment by trypsin may affect
internalization rates of surface receptors, we also employed a
biochemical internalization assay based on biotinylation of
surface proteins [43, 53]. Indeed, silencing of Brag2 signifi-
cantly reduced the internalization of the b1-integrin subunit
in comparison to scrambled siRNA-transfected HUVEC
(Fig. 4d). Since silencing of Brag2 increased focal/fibrillar
adhesions in HUVEC adhering to the a5b1-integrin ligand
fibronectin (Fig. 2f, g) and since focal and fibrillar adhesions
contain activated (matrix-bound) integrins [2], we also spe-
cifically explored the role of Brag2 for the internalization of
activated/matrix-bound a5b1-integrin by using an antibody,
which recognizes activated a5b1-integrins localized in
fibrillar and partly in focal adhesions (clone SNAKA51) [12].
Silencing of Brag2 significantly reduced the internalization
of activated a5b1-integrins (Fig. 4e). Interestingly, silencing
of Brag2 reduced the internalization of activated a5b1-inte-
grins even in the presence of the recycling inhibitor primaq-
uine, suggesting that Brag2 is mediating internalization
without affecting recycling of activated a5b1-integrin (data
not shown). In summary, our data indicate that Brag2 may
promote EC migration and angiogenesis by mediating b1-
integrin endocytosis thereby contributing to the turnover of
focal/fibrillar adhesions and regulating b1-integrin-depen-
dent EC adhesion. Interestingly, silencing of Brag2 did not
significantly affect endocytosis of aVb3-integrins (data not
shown), but significantly reduced their recycling (Supple-
mental Figure S2F). Taking together, Brag2 mediates endo-
cytosis of b1-integrins and recycling of aVb3-integrins.
Brag2 promotes endocytosis of b1-integrins in EC
and angiogenic sprouting in an Arf-GTPase-dependent
manner
To gain insight in the molecular mechanisms involved in
Brag2-mediated b1-integrin endocytosis, we studied the
domains of Brag2 required in this process. Therefore, we
overexpressed following constructs in COS7 cells: WT-
Brag2a-GFP, Brag2a-DSec-GFP lacking the catalytic
domain Sec7, which is essential for the activation of
GTPases of the Arf family, Brag2a-DPH-GFP lacking the
pleckstrin homology domain, which is required for the
activation of the enzymatic activity of Brag2 by binding
PI(4,5)P2 on membranes [26, 45], or EGFP control vector
and assessed b1-integrin endocytosis in a pulse-chased
endocytosis assay by FACS in GFP? cells. Overexpression
of WT-Brag2a-GFP increased the internalization of b1-
integrin in comparison to EGFP-transfected COS7 cells
(Fig. 5a). Overexpression of Brag2a-DSec7-GFP or
bFig. 5 Role of Arf GTPases for Brag2-mediated b1-integrin inter-
nalization, angiogenic sprouting and regulation of focal/fibrillar
adhesions. a Pulse-chased endocytosis assay of the b1-integrin
subunit in COS7 cells as determined with FACS. Briefly, Cos7 cells
were transfected with wild-type Brag2a-GFP, Brag2a-DSec-GFP,
Brag2a-DPH-GFP or EGFP empty vector. After 24 h, a pulse-chased
endocytosis assay of the b1-integrin subunit was performed for
10 min and the MFI of internalized b1-integrin was determined in
GFP? COS7 cells by FACS. Data are presented as mean internalized
b1-integrin % of total surface b1-integrin ± SEM (*P \ 0.05 vs.
EGFP; #P \ 0.05 vs. GFP-Brag2a, n = 7). b HUVEC were trans-
fected with scrambled or Brag2 siRNA. After 24 h, cells were
transiently transfected where indicated with EGFP empty vector,
rapid cycling Arf5-T161A-GFP mutant, or a rapid cycling Arf6-
T157A-GFP mutant. After 24 h, immunofluorescent staining was
performed with an antibody recognizing activated/matrix-bound
a5b1-integrin (clone SNAKA51) present in focal and fibrillar
adhesions. The focal adhesion area in GFP? and GFP- cells of each
condition was quantified by confocal microscopy. Data are presented
as focal adhesion area % total cell area ± SEM (*P \ 0.05 vs.
siBrag2 ? EGFP-GFP? and siBrag2 ? Arf5-T161A-EGFP-GFP-;
n = 3–4). c Representative images for Fig. 5b. Microphotographs
demonstrating focal and fibrillar adhesions were acquired at the basal
surface of the cells, where focal/fibrillar adhesions are localized. Red
fluorescence indicates the active/matrix-bound a5-integrin, green
fluorescence indicates GFP? cells (for each condition). d Overexpres-
sion in HUVEC of wild-type myc-Brag2 or pcDNA3.1 empty vector
in combination with siRNAs targeted against Arf5, Arf6 or scrambled
control. Angiogenic sprouting of endothelial-cell spheroids was
determined. Data are presented as mean % pcDNA3.1 ? scrambled
siRNA ± SEM (*P \ 0.05 vs. myc-Brag2 ? scrambled siRNA;
n = 6–7)
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Brag2a-DPH-GFP did not promote the endocytosis of b1-
integrins (Fig. 5a), indicating that Brag2 is mediating
endocytosis of b1-integrins by activation of Arf-GTPases.
Consistent with these results, overexpression of the rapid
cycling mutant Arf5-T161A-GFP significantly reduced the
increased SNAKA51-positive focal/fibrillar adhesions
observed upon silencing of Brag2 (Fig. 5b, c). Moreover,
also the rapid cycling mutant Arf6-T157A-GFP reduced,
even if not significantly, focal/fibrillar adhesions induced
by Brag2-silencing (Fig. 5b, c). To explore the role of Arf5
and Arf6 as possible downstream effectors of Brag2 in
angiogenesis, we overexpressed myc-Brag2a in combina-
tion with scrambled siRNA, Arf5 siRNA or Arf6 siRNA in
HUVEC and assessed angiogenic sprouting. Whereas
overexpression of Brag2a enhanced angiogenic sprouting
in scrambled siRNA-transfected cells, silencing of Arf5 or
Arf6 blocked Brag2a-induced sprouting (Fig. 5d and Sup-
plemental Figures S2G, S2H and S2I). Taken together,
Arf5 and Arf6 are acting downstream of Brag2 in EC
thereby promoting b1-integrin endocytosis, regulating
focal adhesions and promoting angiogenic sprouting.
Role of Brag2 for developmental angiogenesis
in zebrafish
Having demonstrated that Brag2 regulates in vitro angio-
genesis, EC migration and matrix adhesion, we next
explored whether Brag2 contributes to endothelial sprout-
ing and vessel formation in vivo. For this purpose, we
studied the effect of Brag2/IQSEC1 silencing during
embryonic development of zebrafish in the transgenic
tg(fli1:EGFP) zebrafish line expressing EGFP in vessels
under control of the fli-1 promoter. We identified 2
orthologue IQSEC1 genes (Brag2/GEP100) in zebrafish
using the ENSEMBL database: ENSDARG00000016551
(IQSEC1a) and ENSDARG00000073822 (IQSEC1b). RT-
PCR of FACS-sorted EGFP-positive EC from the devel-
oping tg(fli1:EGFP) zebrafish at 24hpf [51] revealed that
IQSEC1a and IQSEC1b mRNA are present in EC in zeb-
rafish yielding a band of 367 and 403 bp, respectively
(Supplemental Figure S3). To determine the role of these
genes in developmental angiogenesis, we designed specific
splice-blocking morpholinos targeting these genes.
Knockdown of IQSEC1a or IQSEC1b or both was achieved
by injection of splice-blocking morpholinos resulting in an
aberrant splicing of the IQSEC1a and IQSEC1b mRNA,
respectively (Supplemental Figure S4A and S4B).
Silencing of IQSEC1a using the splice-blocking IQ-
SEC1a-MO-A morpholino led to vascular defects in 48hpf
old tg(fli1:EGFP) zebrafish embryos. Specifically, silenc-
ing of IQSEC1a significantly induced defects of the dorsal
longitudinal anastomotic vessel (DLAV) and intersomitic
vessels (ISV) (Fig. 6a, c, d) and significantly reduced the
formation of the parachordal lymphangioblasts (PL), the
precursor to the lymphatic system at 48hpf and 72hpf
(Fig. 6e, Supplemental figure S6C and S6D). For a control
of the specificity of the IQSEC1a-MO-A morpholino, we
designed a second splice-blocking morpholino (IQSEC1a-
MO-B) silencing IQSEC1a expression, which led to similar
results in the vasculature in tg(fli1:EGFP) embryos
(Fig. 6a, c–e and Supplemental Figure S6A, S6B, S6C and
S6D). Silencing of IQSEC1b with two distinct splice-
blocking morpholinos (IQSEC1b-MO-A and IQSEC1b-
MO-B) led to a milder vascular phenotype. Specifically,
silencing of IQSEC1b only significantly impaired forma-
tion of the parachordal vessel/parachordal lymphangioblast
(PL) at 48hpf and 72hpf (Fig. 6e, Supplemental Figures
S6C and S6D) but did not significantly affect the formation
of ISV and DLAV (Fig. 6a, Supplemental figures S6A and
S6B). Strikingly, silencing of both IQSEC1a and IQSEC1b
led to a more severe vascular phenotype strongly affecting
vascular patterning in tg(fli1:EGFP) zebrafish embryos
(Fig. 6b). Indeed, silencing of IQSEC1a and IQSEC1b
genes induced more severe defects in the ISV and in the
DLAV (Fig. 6b–d) and led to a highly penetrant absence of
the PL (Fig. 6e). In addition, silencing of both genes, IQ-
SEC1a and IQSEC1b, led to defects in the formation of the
common cardinal vein (CCV) in tg(fli1:EGFP) zebrafish
embryos at 48hpf (Fig. 6f, g). Remarkably, silencing of
both genes, IQSEC1a and IQSEC1b also led to vascular
edema in the tail and to formation of hydrocephalus
(Supplemental Figure S5A and Figure S5B). Taken toge-
ther, the Brag2 orthologue genes IQSEC1a and IQSEC1b
play an essential synergistic role in the developmental
angiogenesis of the zebrafish and in vessel stability and
affect vascular patterning.
Inhibition of Brag2 in vivo reduces pathological
angiogenesis in mice
Next, we attempted to address whether Brag2 is also
involved in pathological angiogenesis. The ROP model
mimics the ischemia-induced angiogenesis observed in
retinopathy of prematurity. Intravitreal injection of Brag2
shRNA reduced the in vivo expression of murine Brag2 by
73.5 % as assessed by qPCR (Supplemental Figure S7).
Intravitreal injection of Brag2 shRNA significantly inhib-
ited retinal neovascularization in comparison to empty
vector (Fig. 7a, b). In addition, laser-induced choroidal
neovascularization is a disease model of the wet form of
age-related macular degeneration. In this model, a laser is
used to disrupt the Bruch’s membrane leading to the
invasion of the choroidal vasculature into the subretinal
pigment epithelium. Injection of Brag2 shRNA led to a
significant reduction of choroidal neovascularization in
comparison to mice treated with the control vector (Fig. 7c,
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Fig. 6 Brag2 (IQSEC1a and IQSEC1b) regulates developmental
angiogenesis in tg(fli1:EGFP) zebrafish embryos. a Representative
bright field and confocal fluorescence images of vessels in the
posterior part of tg(fli1:EGFP) zebrafish embryos after injection of
indicated splice-blocking morpholinos or control morpholino at
48hpf. Arrows indicate vessel defects. b Representative bright field
and confocal fluorescence images of vessels in the posterior part of
tg(fli1:EGFP) zebrafish embryos after injection of IQSEC1a–MO-B
and IQSEC1b–MO-B morpholinos or control morpholino at 48hpf.
Arrows indicate vessel defects. c, d Quantification of defects in ISVs
(c) and DLAVs (d) in IQSEC1a, or IQSEC1a ? IQSEC1b and
control morphants. The data are presented as the number of defects
per zebrafish ± SD (*P \ 0.05 vs. respective control Mo,
n = 73–111; #P \ 0.05 vs. respective control Mo, n = 93–112).
e Quantification of parachordal lymphangioblasts (PL) for IQSEC1a,
IQSEC1b, IQSEC1a ? IQSEC1b and control morphants at 48hpf and
72hpf. The data are presented as the number of PL ± SD (*P \ 0.05
vs. respective control morpholino, 48 hpf, #P \ 0.05 vs. respective
control morpholino, 72hpf; n = 63–135). f Representative confocal
fluorescence images of the common cardinal vein (CCV) in control
morphants (left) and in IQSEC1a-MO-B ? IQSEC1b-MO-A mor-
phants (right) at 48hpf. g Quantification of CCV defects in
IQSEC1a ? IQSEC1b morphants and control morphants at 48hpf.
The data are presented as mean ± SD (*P \ 0.05 vs. control
morpholino, 48hpf; n = 35–43)
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d). Taking together, Brag2 is also involved in pathological
angiogenesis.
Discussion
The present study underscores the relevance of Brag2 for
regulation of integrin function in EC and in angiogenesis.
Specifically, our findings revealed that: (1) endothelial
Brag2 mediates migration and in vitro angiogenic sprout-
ing in an Arf-GTPase-dependent manner partly by regu-
lating the surface expression of a5b1-integrins; (2) Brag2
differentially regulates a5b1- and aVb3-integrins in EC.
Specifically, Brag2 promotes the endocytosis of active/
matrix-bound a5b1-integrins, thereby regulating a5b1-
integrin abundance on the cell surface, contributing to the
turnover of focal adhesions, and reducing b1-integrin-
dependent adhesion. In contrast, Brag2 promotes the
recycling of aVb3-integrins, thereby increasing aVb3-
integrin cell surface abundance and promoting EC adhe-
sion on the aVb3-integrin ligand vitronectin; (3) Brag2
genes (IQSEC1a and IQSEC1b) are essential for develop-
mental angiogenesis in zebrafish, thereby contributing to
vascular patterning and finally; (4) inhibition of Brag2
in vivo reduces pathological retinal angiogenesis and
choroidal neovascularization. Thus, the present study pro-
vides insights into the mechanisms of integrin endocytosis
in EC and their contribution to the process of angiogenesis
and unravels a novel function of Brag2 as key mediator of
physiological and pathological neovascularization. More-
over, inhibition of Brag2 seems to be a promising thera-
peutic target for treatment of pathological angiogenesis.
Adhesion to fibronectin and VEGF was shown to stimulate
activation of the Arf6 GTPase [18, 20, 27]. Our present work
shows that Brag2 is required for basal and VEGF-induced
Arf6 activity in EC. These data are consistent with the data of
Hashimoto et al. [20] demonstrating that VEGF stimulation
leads to the association of VEGFR2 to Brag2 thereby medi-
ating Arf6 activation. Interestingly, a pharmacological
inhibitor of the Arf6-GEFs cytohesins 1–3, SecinH3, reduced
VEGF-induced activation of Arf6 in EC [27], suggesting that
not only Brag2, but also Arf6-GEFs of the cytohesin family
may contribute to the VEGF-induced stimulation of Arf6
activity.
Remarkably, silencing of Brag2 blocked angiogenic
sprouting and tube-forming activity of EC. In line with
these results, knock down of the orthologue genes of Brag2
(IQSEC1a and/or IQSEC1b) in zebrafish perturbed
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Fig. 7 Silencing of Brag2 suppresses pathological angiogenesis in
the ROP model and choroidal neovascularization. a Representative
images of whole-mount retinae stained with IB4 after intravitreal
injection of vector containing Brag2 shRNA or control empty vector
in the ROP model. White arrows indicate neovascular tufts. b Quan-
tification of the neovascularization area after intravitreal injection of a
Brag2 shRNA or control plasmid in the ROP model. Data are
presented as mean neovascularization area % total area ± SEM
(*P \ 0.05 vs. empty plasmid, n = 8). c Representative images of
choroidal neovascularizations stained with IB4 after intravitreal
injection of a plasmid containing Brag2 shRNA or an control plasmid
(PLKO.1) in the choroidal neovascularization model. d Quantification
of the neovascularization area after intravitreal injection of a plasmid
containing Brag2 shRNA or control plasmid in the choroidal
neovascularization model. Data are presented as neovascularization
area (lm2) ± SEM (*P \ 0.05 vs. empty plasmid, n = 16–20)
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developmental angiogenesis and vascular patterning.
Interestingly, silencing of IQSEC1a and IQSEC1b also
impaired the formation of the parachordal vessel/para-
chordal lymphangioblasts, which is considered as a pre-
cursor of the lymphatic system [55] and additionally led to
vascular edema and hydrocephalus. Beyond developmental
angiogenesis, in vivo silencing of Brag2 significantly
reduced pathological angiogenesis in the disease model of
retinopathy of prematurity and in the model of choroidal
neovascularization. Consistent with our results, also in a
model of Angioreactor-induced angiogenesis, silencing of
Brag2 inhibited neovascularization [20]. Furthermore, the
pharmacological inhibition of Arf6-GEFs of the cytohesin
family with SecinH3 reduced angiogenesis [27]. Intrigu-
ingly, not only inhibition but also an over-activation of the
Brag2/Arf6 pathway, as achieved by stimulation with
Semaphorin 3E, blocks angiogenesis [44, 45]. In conclu-
sion, a stringent and balanced activation of Arf-GTPases by
Brag2 is mandatory for efficient angiogenesis.
A relevant question is how Brag2 promotes angiogenesis.
EC migration is essential for angiogenesis. We found that
Brag2 promotes 2- and 3-dimensional EC migration, while
not affecting proliferation. Cell migration requires the
dynamic establishment of new integrin-mediated focal
adhesions by binding of integrins to ECM proteins in the
migrating front, concomitant with the disassembly/turnover
of mature focal/fibrillar adhesions allowing cell retraction
and forward movement [8, 9]. Integrin trafficking is involved
in the assembly/disassembly of focal/fibrillar adhesions.
Indeed, focal/fibrillar adhesion disassembly includes the
internalization/endocytosis of integrins [8–10, 17, 53].
Strikingly, we provide here direct evidence that Brag2 partly
mediates angiogenesis by reducing a5b1-integrin surface
expression. Specifically, we show that Brag2 promotes b1-
integrin endocytosis in EC, thereby reducing focal/fibrillar
adhesions and EC adhesion to b1-integrin ligands. In addi-
tion, silencing of Brag2 also slightly increased a3b1- and
a6b1-integrin on the EC surface (data not shown). In line with
our results, Dunphy et al. [15] demonstrated that silencing of
Brag2 in HeLa cells increased surface expression of b1-
integrins and cell spreading. Moreover, another study sug-
gested that Brag2 may promote b1-integrin endocytosis [33].
Remarkably in our present work, we demonstrated that Brag2
is involved in the internalization/endocytosis of activated
(matrix-bound) a5b1-integrins, as assessed by an activation-
dependent a5b1-integrin antibody recognizing an active
a5b1-integrin conformation present in fibrillar and partly in
focal adhesions [12], supporting the idea that Brag2 con-
tributes to the disassembly of focal/fibrillar adhesions by
mediating endocytosis of active/matrix-bound a5b1-inte-
grins. Interestingly, silencing of Brag2 also reduced the
recycling of aVb3-integrins to the cell surface and conse-
quently decreased the cell surface expression of aVb3-
integrins and adhesion to vitronectin. However, in our hands
inhibition of aVb3-integrins (in contrast to b1-integrin
inhibition) did not affect angiogenic sprouting. In summary,
our data indicate that Brag2 promotes EC migration and
angiogenesis by mediating b1-integrin endocytosis thereby
contributing to the turnover of focal/fibrillar adhesions and
regulating a5b1-integrin-dependent EC adhesion.
An important question is how Brag2 mediates integrin
endocytosis. In this regard, we found that the integrin
endocytosis-promoting activity of Brag2 is dependent on
the activation of Arf-GTPases. However, the effector pro-
teins downstream of Arf-GTPases signaling mediating
integrin internalization in EC are unclear. Arf6 was shown
to contribute via PIP5K and recruitment of AP2 and
clathrin to receptor endocytosis [22, 29, 39]. Moreover, a
recent study demonstrated that Brag2 could bind clathrin
and AP2 itself and that Arf5, an Arf-GTPase also activated
by Brag2, may contribute to b1-integrin endocytosis [33].
In line with these results, we found here that Arf5 and Arf6
mediate downstream of Brag2 angiogenic sprouting and
the regulation of focal/fibrillar adhesions containing acti-
vated a5b1-integrins in EC. Interestingly, it was shown that
Arf6 may also mediate recycling of b1-integrins to the cell
surface [40]. Additional studies are mandatory in order to
define the downstream mechanisms promoting Brag2-
dependent integrin endocytosis.
An additional mechanism by which Brag2 may affect
angiogenesis includes the regulation of vascular perme-
ability. Indeed, silencing of Brag2 increases in vitro per-
meability of EC monolayers ([20] and our unpublished
data), while reducing the surface abundance of VE-Cad-
herin [20]. Moreover, silencing of Brag2 (IQSEC1a and
IQSEC1b) in zebrafish led to hydrocephalus and vascular
edema, probably as a consequence of vascular hyperper-
meability. Nevertheless, the permeability regulating activ-
ity of Brag2 does not explain the observed inhibition of EC
migration and angiogenic sprouting induced by the knock-
down of Brag2 in our study. Indeed, VE-Cadherin-induced
cell–cell interactions were shown to block EC migration
and angiogenic sprouting [1]. So, one would expect that,
since silencing of Brag2 reduces VE-Cadherin-mediated
cell–cell adhesion (adherens junctions) and increases vas-
cular permeability ( [20] and our unpublished data), would
rather lead to a promigratory and proangiogenic EC phe-
notype. However, as we clearly demonstrated in our present
work silencing of Brag2 blocked angiogenic sprouting, EC
migration and in vivo angiogenesis. Furthermore, specifi-
cally Arf6 was shown to modify VEGFR2 function in
endothelial cells [25]. However, silencing of Brag2 did not
reduce VEGF-induced VEGFR2 phosphorylation and Akt
activation (data not shown), suggesting that the inhibitory
effect of Brag2 knockdown on angiogenic sprouting cannot
be ascribed to an inhibition of VEGFR2-induced signaling.
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Surprisingly, Brag2 exerted opposing effects on b1- and
b3-integrins in EC. A potential explanation for these
opposing effects is that the trafficking of a5b1- and aVb3-
integrins are inversed coupled to each other [54]. However,
additional studies will be required to clarify the underlying
molecular mechanisms in EC. Based on the fact that b1-
integrins are essential for angiogenesis [4, 49, 52], we
focused in the present study on the effects of Brag2 on b1-
integrins in EC.
Taken together, our data demonstrate that Brag2 is a key
mediator of developmental and pathological angiogenesis
by promoting b1-integrin endocytosis thereby regulating
b1-integrin-containing focal/fibrillar adhesions, and con-
sequently EC migration and sprouting. Thus, our present
work provides evidence that mechanisms involved in
integrin endocytosis are essential in angiogenesis and that
increased EC adhesion as a consequence of reduced inte-
grin endocytosis may negatively affect angiogenesis. In
line with our results, Palecek et al. [38] demonstrated that
high cell-substratum adhesiveness impairs cell motility,
and that maximum cell speed occurs at intermediate
adhesiveness. Since silencing of Brag2 did not completely
abolish b1-integrin internalization in EC, additional path-
ways may also contribute to this process as reported else-
where [36, 53]. Finally, Brag2 inhibition seems to be a
promising target for the development of new antiangio-
genic approaches to treat patients with pathological angi-
ogenesis such as in proliferative retinopathies and in
cancer.
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